# A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine

> **NCT00001994** · NA · COMPLETED · sponsor: **Glaxo Wellcome**

## Conditions studied

- Toxoplasmosis, Cerebral
- HIV Infections

## Interventions

- **DRUG:** Atovaquone

## Key facts

- **NCT ID:** NCT00001994
- **Lead sponsor:** Glaxo Wellcome
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001994, "A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00001994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*